Compounds and methods for detecting nitric oxide

Aminoluciferin and aminocyanobenzothiazole derivatives offer a specific and quantitative method for nitric oxide detection by forming a stable reporter product, overcoming false positives and enabling accurate NO measurement.

JP2024540826APending Publication Date: 2024-11-06PROMEGA CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024519880
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-01
Filing Date
2022-09-30
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Current methods for detecting nitric oxide (NO) are not specific and often produce false positives, and there is a need for quantitative assays that can accurately measure NO levels in various samples.

Method used

Development of compounds, particularly aminoluciferin and aminocyanobenzothiazole derivatives, which selectively react with NO to form a stable reporter product, allowing for luminescence-based detection in a homogeneous format.

Benefits of technology

The compounds provide high specificity for NO detection, avoiding interference from other reactive species and enabling accurate, quantitative measurement of NO levels through bioluminescence without the need for external light.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540826000024
    Figure 2024540826000024
  • Figure 2024540826000025
    Figure 2024540826000025
  • Figure 2024540826000026
    Figure 2024540826000026
Patent Text Reader

Abstract

Disclosed herein are compounds that can be used to selectively detect nitric oxide in a sample. Also disclosed herein are compositions that include the compounds and methods for detecting nitric oxide using the compounds.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 251,395, filed October 1, 2021, which is incorporated by reference in its entirety.

[0002] Disclosed herein are compounds that can be used to selectively detect nitric oxide in a sample. Also disclosed herein are compositions that include the compounds and methods for detecting nitric oxide using the compounds. [Background technology]

[0003] Nitric oxide (NO) is a reactive molecule with a half-life of approximately 2-6 seconds and is formed from L-arginine by nitric oxide synthases (eNOS, iNOS, and nNOS). NO is an important signaling molecule that regulates vasoconstriction and immune responses. NO plays an important role in oxidative stress because it rapidly reacts with superoxide to form cytotoxic peroxynitrite. Therefore, methods for the direct detection of cellular nitric oxide are highly sought after. Current methods for detecting NO include the Griess reaction and indirect colorimetric measurements using various NO-reactive fluorophores with detection of end products (nitrite and nitrate). However, some commonly used probes, such as those containing o-phenylenediamine-based reactive moieties, tend to react with bis-electrophiles such as dehydroascorbic acid and generate false positives. Therefore, a quantitative and specific assay for the detection of NO is needed. Summary of the Invention

[0004] In one aspect, the present disclosure provides a compound of formula (I); [ka] or a salt thereof, wherein: R 1 is -CN and [ka] Selected from; R 2 is selected from hydrogen and halo; R 3 is selected from hydrogen, C1-C6 alkyl, and hydroxy-C1-C6-alkyl; n is 0, 1, 2, or 3; Each R 4 are independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, halo, hydroxy, amino, cyano, nitro, -COOR a , and -CONR b R c Selected from; R 5 is selected from hydrogen and C1-C4 alkyl; and R a , R b , and R c are each independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and C1-C6 heteroalkyl.

[0005] In some embodiments, R 1 In some embodiments, R 1 teeth [ka] In some embodiments, R 5 is selected from hydrogen and methyl.

[0006] In some embodiments, R 2 is hydrogen.

[0007] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is hydroxy-C2-C4-alkyl. In some embodiments, R3 is -CH2CH2CH2OH.

[0008] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, R 4 is selected from methoxy and nitro.

[0009] In some embodiments, the compound is [ka] and salts thereof.

[0010] In another aspect, there is provided a method for detecting nitric oxide in a sample, comprising the steps of: contacting the sample with a compound disclosed herein (e.g., a compound of formula (I)), or a salt thereof; contacting the sample with a luciferin-utilizing luciferase, if not already present in the sample; detecting luminescence in the sample; and The above method is disclosed herein, comprising:

[0011] In some embodiments, the sample comprises living cells. In some embodiments, the cells express a luciferin-utilizing luciferase. In some embodiments, the method comprises adding a luciferin-utilizing luciferase to the sample. In some embodiments, the luciferin-utilizing luciferase is firefly luciferase or click beetle luciferase.

[0012] In another aspect, disclosed herein are kits that include a compound disclosed herein (e.g., a compound of Formula (I)), or a salt thereof. In some embodiments, the kit further includes a luciferin-utilizing luciferase enzyme or a nucleotide sequence encoding a luciferin-utilizing luciferase enzyme. In some embodiments, the kit further includes a buffer reagent.

[0013] Other aspects and embodiments will become apparent in view of the following description and drawings. [Brief description of the drawings]

[0014] [Figure 1] 1 shows a schematic overview of a method for detecting intracellular nitric oxide using compounds such as those disclosed herein. [Diagram 2] A schematic overview of a luminescence assay to detect nitric oxide in a sample of cells or other specimen is shown. The "treatment" step refers to the addition of unknown experimental components (e.g., drug candidates), which can be added before, after, or simultaneously with the nitric oxide probe. [Diagram 3] 1 shows data from an assay to detect nitric oxide in cell-free samples, as described in Example 2. [Figure 4] 1 shows data from an assay detecting intracellular nitric oxide following synergistic NO stimulation by lipopolysaccharide (LPS) and interferon gamma (INFγ), as described in Example 3. [Diagram 5] 5A-5B show a schematic diagram of SIN-1 induction of superoxide (SO) and NO using MitoTEMPO as a superoxide scavenger to increase NO levels (FIG. 5A) and data from assays detecting NO in five different cell lines treated with SIN-1 and MitoTEMPO, as shown in Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Disclosed herein are probe compounds, particularly caged aminoluciferin and aminocyanobenzothiazole compounds, and derivatives thereof, that have high specificity for the detection of nitric oxide over other reactive nitrogen and oxygen species. Upon reaction with nitric oxide, a stable reporter product is formed, allowing the assay to be performed in a homogeneous "add and read" plate-based format or in a kinetic mode with media sampling.

[0016] definition Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the embodiments described herein, some preferred methods, compositions, devices, and materials are described herein. However, before describing the materials and methods, it should be understood that the invention is not limited to the specific molecules, compositions, methodologies, or procedures described herein, as these may vary according to routine experimentation and optimization. It should also be understood that the terminology used in the specification is merely for the purpose of describing a particular mode or embodiment, and is not intended to limit the scope of the embodiments described herein.

[0017] Unless otherwise defined herein, scientific and technical terms used in connection with this disclosure shall have the meanings commonly understood by those skilled in the art. For example, any technical terms used in connection with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein, and these techniques are well known and commonly used in the art. The meaning and scope of the terms must be clear, but in the event of any potential ambiguity, the definitions provided herein shall take precedence over any dictionary or external definitions. Furthermore, unless otherwise required by context, singular terms shall include the plural and plural terms shall include the singular.

[0018] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a peptide" refers to one or more peptides and equivalents thereof known to those skilled in the art.

[0019] As used herein, the term "and / or" includes any and all combinations of the listed items, including any of the individually listed items. For example, "A, B, and / or C" includes A, B, C, AB, AC, BC, and ABC, each of which is considered to be separately denoted by the statements "A, B, and / or C."

[0020] As used herein, the term "comprise" and its linguistic variations indicate the presence of the recited feature(s), element(s), method step(s), etc., without excluding the presence of additional feature(s), element(s), method step(s), etc. In contrast, the term "consisting of" and its linguistic variations indicate the presence of the recited feature(s), element(s), method step(s), etc., but excluding any unrecited feature(s), element(s), method step(s), etc., except for impurities normally associated therewith. The phrase "consisting essentially of" refers to the recited feature(s), element(s), method step(s), etc., as well as any additional feature(s), element(s), method step(s), etc. that do not materially affect the basic nature of the composition, system, or method. Many embodiments herein are described using the open term "comprising." Such embodiments encompass multiple embodiments in the closed form "consisting of" and / or "consisting essentially of," which may alternatively be claimed or described using such language.

[0021] For the recitation of numerical ranges herein, each intervening numerical value therebetween to the same degree of precision is expressly contemplated. For example, for the range 6 to 9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0 to 7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are expressly contemplated.

[0022] "Luminescence" refers to the light output of a luciferase enzyme under appropriate conditions, for example, in the presence of a suitable substrate, such as luciferin (e.g., aminoluciferin) or an aminocyanobenzothiazole compound (e.g., generated after reaction of nitric oxide with a compound of formula (I)). Light output can be measured as an instantaneous or near-instantaneous measurement of light output (sometimes referred to as "T=0" luminescence or "flash") at the start of the luminescence reaction, which may begin upon addition of luciferin substrate. The reaction chamber (e.g., a plate such as a 96-well plate) can be placed in a reader that can measure light output, for example, using a luminometer or photomultiplier tube. Light output or luminescence can be measured over time, for example, over a period of seconds, minutes, hours, etc. in the same reaction chamber. Light output or luminescence can be reported as an average over time, a half-life of the signal decay, a sum of the signal over a period of time, or a peak output. Luminescence can be measured as relative light units (RLU).

[0023] As used herein, the term "sample" is used in its broadest sense. In one sense, it is meant to include specimens or cultures obtained from any source, as well as biological and environmental samples. Biological samples can be obtained from animals (including humans) and can include fluids, solids, tissues, and gases. Biological samples include blood products (plasma, serum, etc.), and the like. Samples can also refer to cells, cell lysates, or purified forms of enzymes, peptides, and / or polypeptides described herein (e.g., purified protein samples). Cell lysates can include cells that have been lysed with a lysing agent, or lysates such as rabbit reticulocyte or wheat germ lysates. Samples can also include in vitro samples and cell-free samples, such as cell-free expression systems. Environmental samples include environmental materials, such as surface materials, soil, water, crystals, and industrial samples. Samples can also include purified samples, such as purified protein samples. However, these examples should not be construed as limiting the types of samples applicable to the present invention.

[0024] Definitions of certain functional groups and chemical terms are explained in more detail below. For purposes of this disclosure, elements are defined as defined in the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 75 th In accordance with the endpapers of Ed., specific functional groups are generally defined as set forth in the Handbook. Further, general principles of organic chemistry, as well as specific functional moieties and reactivities, are defined in accordance with Sorrell, Organic Chemistry, 2000, ed. nd edition,University Science Books,Sausalito,2006;Smith,March's Advanced Organic Chemistry:Reactions,Mechanism,and Structure,7 th Edition,John Wiley & Sons,Inc.,New York,2013;Larock,Comprehensive Organic Transformations,3 rd Edition, John Wiley & Sons, Inc., New York, 2018; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987, the entire contents of each of which are incorporated herein by reference.

[0025] As used herein, the term "alkyl" refers to a straight or branched chain saturated hydrocarbon. An alkyl chain may, for example, contain 1 to 30 carbon atoms (C1-C 30 Alkyl), 1 to 24 carbon atoms (C1-C 24 alkyl), e.g., alkyl having 1 to 16 carbon atoms (C1-C 16 Alkyl), 1 to 14 carbon atoms (C1-C 14 Alkyl), 1 to 12 carbon atoms (C1-C 12 Alkyl), 1 to 10 carbon atoms (C1-C 10alkyl), 1 to 8 carbon atoms (C1-C8 alkyl), 1 to 6 carbon atoms (C1-C6 alkyl), or 1 to 4 carbon atoms (C1-C4 alkyl). Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl.

[0026] As used herein, the term "alkenyl" refers to a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond. The double bond(s) can be located at any position within the hydrocarbon chain. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

[0027] As used herein, the term "alkynyl" refers to a straight or branched hydrocarbon chain containing at least one carbon-carbon triple bond. The triple bond(s) can be located at any position within the hydrocarbon chain. Representative examples of alkynyl include, but are not limited to, ethynyl, propynyl, and butynyl.

[0028] The term "alkoxy" as used herein means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, and tert-butoxy.

[0029] As used herein, the term "amino" refers to the group -NR x R ywherein R x and R y is selected from hydrogen and alkyl (e.g., C1-C4 alkyl).

[0030] As used herein, the term "aryl" refers to an aromatic carbocyclic ring having a single ring (monocyclic) or multiple rings (bicyclic or tricyclic), including fused ring systems, and no heteroatoms. As used herein, aryl refers to an aromatic carbocyclic ring having 6 to 20 carbon atoms (C6-C 20 Aryl), 6 to 14 ring carbon atoms (C6-C 14 Aryl), 6 to 12 ring carbon atoms (C6-C 12 aryl), or 6 to 10 ring carbon atoms (C6-C 10 Representative examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, and phenanthrenyl.

[0031] As used herein, the term "cycloalkyl" refers to a saturated carbocyclic ring containing 3 to 10 carbon atoms and no heteroatoms. Cycloalkyls can be monocyclic, bicyclic, bridged, fused, or spirocyclic. Representative examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl, and bicyclo[5.2.0]nonanyl.

[0032] As used herein, the term “halogen” or “halo” means F, Cl, Br, or I.

[0033] As used herein, the term "haloalkyl" refers to an alkyl group, as defined herein, in which at least one hydrogen atom (e.g., 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms) is replaced with a halogen. In some embodiments, each hydrogen atom of the alkyl group is replaced with a halogen. Representative examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, and 3,3,3-trifluoropropyl.

[0034] The term "haloalkoxy" as used herein means a haloalkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of haloalkoxy include, but are not limited to, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.

[0035] As used herein, the term "heteroalkyl" refers to an alkyl group, as defined herein, in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with a heteroatom group, such as, for example, -NH-, -O-, -S-, -S(O)-, -S(O)-. For example, one, two, or three carbon atoms may be independently replaced with the same or different heteroatom groups. Examples of heteroalkyl groups include, but are not limited to, -CHOCH, -CHSCH, -CHNHCH, -CHN(CH), -CHS(O)CH, and -CHS(O)CH. Heteroalkyl also includes groups in which an alkyl carbon atom is oxidized (i.e., -C(O)-).

[0036] As used herein, the term "hydroxy" refers to an --OH group.

[0037] As used herein, the term "hydroxyalkyl" means an alkyl group, as defined herein, in which at least one hydrogen atom has been replaced with a hydroxy group.

[0038] When a group or moiety can be substituted, the term "substituted" means that one or more (e.g., 1, 2, 3, 4, 5, or 6; in some embodiments, 1, 2, or 3; and, in other embodiments, 1 or 2) hydrogens in the group designated with the phrase "substituted" can be replaced with a selection of the groups listed and designated, or with suitable substituents known to those of ordinary skill in the art (e.g., one or more of the groups listed below), provided that the normal valence of the designated atom is not exceeded. Substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azide, carbamoyl, carboxyl, carboxylester, cyano, cycloalkyl, cycloalkenyl, guanidino, halo, haloalkyl, haloalkoxy, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, phosphate, phosphate, phosphonate, sulfonic acid, thiol, thione, or combinations thereof.

[0039] As used herein, in chemical structures, the indications: [ka] represents the point of attachment of one moiety to another (e.g., a substituent to the remainder of a compound).

[0040] For the compounds described herein, groups or substituents thereof can be selected according to the permissible valences and substituents of atoms such that selection and substitution result in stable compounds that do not spontaneously undergo transformation, e.g., by rearrangement, cyclization, elimination, and the like.

[0041] Where substituents are specified by their conventional chemical formulae written from left to right, those substituents optionally include the substituents resulting from writing the structure from right to left, e.g., -CHO- optionally also recites -OCH-, -OC(O)NH- optionally also recites -NHC(O)O-. compound

[0042] Compounds of formula (I): [ka] or a salt thereof, wherein: R 1 is -CN and [ka] Selected from; R 2 is selected from hydrogen and halo; R 3 is selected from hydrogen, C1-C6 alkyl, and hydroxy-C1-C6-alkyl; n is 0, 1, 2, or 3; Each R 4 are independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, halo, hydroxy, amino, cyano, nitro, -COOR a , and -CONR b R c Selected from; R 5 is selected from hydrogen and C1-C4 alkyl; and R a , R b , and R c are each independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and C1-C6 heteroalkyl.

[0043] In some embodiments, R 1 In some embodiments, R 1 teeth [ka] In some embodiments, R 5 is selected from hydrogen and methyl. In some embodiments, R5 is hydrogen. In some embodiments, R 5 is methyl.

[0044] In some embodiments, R 2 is hydrogen.

[0045] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is hydroxy-C2-C4-alkyl. In some embodiments, R 3 is -CH2CH2CH2OH.

[0046] In some embodiments, n is 0.

[0047] In some embodiments, n is 1. In some embodiments, R 4 is selected from methoxy and nitro.

[0048] In some embodiments, the compound is [ka] and salts thereof.

[0049] In some embodiments, the compound is in salt form, e.g., the charged form of the parent compound associated with counterion.The neutral form of the compound can be regenerated by contacting the salt with base or acid and isolating the parent compound in a conventional manner.The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salt is the same as the parent form of the compound for the purposes of this disclosure.

[0050] In particular, the compound has a functional group that is anionic or can be anionic (e.g., -COOH can be changed to -COO - In the case of cations such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 29 + , Na +, and K + Alkali metal cations such as Ca 2+ and Mg 2+ Examples of suitable organic cations include, but are not limited to, alkaline earth cations such as ammonium ions (i.e., NH4 + ), as well as substituted ammonium ions (e.g., NH3R1 + , NH2R2 + , NHR3 + , and NR4 + ) are included, but are not limited to. Some suitable substituted ammonium ions are those derived from ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids such as lysine and arginine. In some embodiments, the compound is a potassium salt. In some embodiments, the compound is a sodium salt.

[0051] The compound is cationic or has a functional group that can be cationic (e.g., -NH2 to -NH3 +In some cases, salts can be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from inorganic acids of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid, and phosphorus. Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyloxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptanoic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthalenecarboxylic acid, isethionic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, phenylsulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, tetrafluoroboric acid, toluenesulfonic acid, trifluoromethanesulfonic acid, and valeric acid. In some embodiments, the compound is a halide salt, such as a chloride, bromide, or iodide salt, hi some embodiments, the compound is a tetrafluoroborate or trifluoromethanesulfonate salt.

[0052] The compounds can be prepared by a number of suitable methods, some of which are shown in the examples. The compounds and intermediates can be isolated and purified by methods well known to those skilled in the art of organic synthesis. Examples of conventional methods for isolating and purifying compounds can include, but are not limited to, recrystallization at high or low temperatures, with optional pretreatment with activated carbon, thin layer chromatography, distillation at various pressures, sublimation under vacuum, and chromatography on solid supports such as silica gel, alumina, or silica derivatized with alkylsilane groups by grinding, as described, for example, in "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989) by Furniss, Hannaford, Smith, and Tatchell, pub. Longman Scientific & Technical, Essex CM20 2JE, England.

[0053] The reaction conditions and reaction times for each individual step may vary depending on the particular reactants used and the substituents present in the reactants used. The reactions may be worked up in conventional manner, for example by removing the solvent from the residue and further purified according to methods generally known in the art, such as, but not limited to, crystallization, distillation, extraction, trituration and chromatography. Unless otherwise stated, starting materials and reagents are either commercially available or can be prepared by one skilled in the art from commercially available materials using methods described in the chemical literature.

[0054] Standard experimentation, including proper manipulation of reaction conditions, reagents and sequences of synthetic routes, protection of any chemical functional groups that may not be compatible with the reaction conditions, and deprotection at appropriate points in the reaction sequence of the method, is within the scope of this disclosure. Suitable protecting groups and methods for protecting and deprotecting different substituents using such suitable protecting groups are well known to those skilled in the art, examples of which can be found in the book by Greens entitled Protective Groups in Organic Synthesis (4 thed.), John Wiley & Sons, NY (2006).

[0055] If an optically active form of a disclosed compound is required, this can be obtained by carrying out one of the procedures described herein using optically active starting materials (prepared, for example, by asymmetric induction of an appropriate reaction step) or by resolving a stereoisomeric mixture of the compound or intermediate using standard procedures (such as chromatographic separation, recrystallization, or enzymatic resolution).

[0056] Similarly, if a pure geometric isomer of a compound is required, this can be obtained by using a pure geometric isomer as a starting material and carrying out one of the procedures described herein, or by resolving a mixture of geometric isomers of the compound or intermediates using standard procedures, such as chromatographic separation.

[0057] The synthetic schemes and specific examples described are illustrative and should not be read as limiting the scope of the disclosure or the claims. Alternatives, variations, and equivalents of the synthetic methods and specific examples are contemplated.

[0058] The present disclosure also includes isotopically labeled compounds that are identical to those recited in formula (I) except for the fact that one or more atoms have been replaced with an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes suitable for incorporation into the compounds of the present invention include, but are not limited to, 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F, and 36Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples, using appropriate isotopically labeled reagents in place of non-isotopically labeled reagents.

[0059] Methods of Use, Systems, and Kits Disclosed herein are methods for detecting nitric oxide using the compounds disclosed herein (e.g., compounds of formula (I)). The compounds include a reactive moiety, in particular [ka] Without wishing to be bound by theory, the compounds are believed to react with nitric oxide as shown in Scheme 1. The product of NO and oxygen (dinitrogen trioxide) reacts rapidly with the reactive moiety sulfur to form an intermediate diaminooxadiazole with the concomitant release of thionitrite, a good leaving group. The oxadiazole rapidly hydrolyzes to release aminoluciferin or aminocyanobenzothiazole, which are substrates for the luciferin-utilizing luciferase enzyme, thereby producing light. Luciferases ("luciferin-utilizing luciferases" or "luciferin-utilizing luciferase enzymes") that utilize luciferin, aminoluciferin, hydroxycyanobenzothiazole, and aminocyanobenzothiazole compounds to produce luminescence include those found in a variety of living organisms, such as insects (e.g., Photinus pyralis and Photuris pennsylvanica (North American fireflies), Pyrophorus plagiophthalamus (Jamaica click beetle), Renilla reniformis (sea pansy), and some bacteria (e.g., Xenorhabdus luminescens and Vibrio spp.).

[0060] Scheme 1. [ka]

[0061] Prior to uncaging by reaction with nitric oxide, the compound of formula (I) is non-reactive with the luciferase enzyme, and luminescence is only observed in the presence of nitric oxide. The reactive moiety has been shown to be selective for nitric oxide over other reactive nitrogen and oxygen species (see, e.g., data in the Examples). Unlike the most commonly used o-phenylenediamine-based reactive moieties, which tend to react with bis-electrophiles such as dehydroascorbic acid to generate false positives, the thiosemicarbazide moiety is less likely to generate false positives due to the two steps that must occur to release the reporter molecule (cyclization to oxadiazole, followed by hydrolysis).

[0062] Another advantage of the compounds of formula (I) is that the uncaged product is detected by bioluminescence and does not require external light (as with fluorescent probes). Furthermore, while nitric oxide species are unstable, upon reaction of the compounds of formula (I) with nitric oxide, the uncaged compound is stable. As NO continues to be produced by the cells, the stable uncaged compound continues to accumulate and can be detected by measuring light production (e.g., using a luciferase reaction). Light production directly correlates with NO production, providing a convenient, quantitative approach to detect short-lived NO. Uncaged aminoluciferin or aminocyanobenzothiazole compounds can be measured using a homogenous "add and read" format by adding detection reagents directly to the sample, or by medium sampling and luciferin detection by measuring the release of luciferin derivatives into the medium at different time points.

[0063] Thus, the present disclosure provides a method for detecting nitric oxide in a sample, the method comprising contacting the sample with a compound of formula (I), contacting the sample with a luciferin-utilizing luciferase, if not already present in the sample, and detecting luminescence in the sample.

[0064] The method includes contacting the sample with a compound of formula (I). The compound of formula (I) can be part of a solution that can include other components, such as, for example, a solvent, a buffer, salts, detergents, additives, etc. For example, the compound of formula (I) can be prepared as a solution in a solvent, such as dimethyl sulfoxide, or as a solution in a buffer, such as phosphate buffered saline. In some embodiments, the method includes first contacting the sample with a compound of formula (I) and incubating the sample for a period of time to allow the nitric oxide to react with the compound of formula (I). In some embodiments, the incubation step can be performed for a period of time ranging from about 1 minute to about 4 days, from about 15 minutes to about 1 day, from about 1 hour to about 12 hours, or any range therebetween. For example, in some embodiments, the incubation step can be performed for about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, or about 12 hours.

[0065] In certain embodiments, the luciferin-utilizing luciferase is not already present in the sample, and optionally the method comprises contacting the sample with a luciferin-utilizing luciferase, hi some embodiments, the luciferin-utilizing luciferase is firefly luciferase or click beetle luciferase.

[0066] When the luciferin-utilizing luciferase is contacted with the sample, it can be included as part of a luciferase reaction mixture. A "luciferase reaction mixture" contains a luciferin-utilizing luciferase enzyme and other materials that enable the luciferase enzyme to generate a light signal. The materials necessary to generate a luminescent signal, as well as the specific concentrations and / or amounts of the materials necessary, will depend on the luciferase enzyme used. Generally, for insect luciferases, additional materials include ATP and magnesium (Mg), such as magnesium sulfate. 2+) salts. In some embodiments, other substances can be added to the solution, including buffers to maintain the reaction at the appropriate pH, additives such as PRIONEX or bovine serum albumin (BSA) to help maintain luciferase activity, reducing agents, detergents, esterases, salts, amino acids (e.g., D-cysteine), and the like. An exemplary luciferase reaction mixture contains insect luciferase, MgSO4, ATP, Tergitol NP-9, and tricine.

[0067] In other embodiments, the luciferin-utilizing luciferase is already present in the sample. For example, in such embodiments, the sample may contain cells that express the luciferin-utilizing luciferase enzyme.

[0068] In some embodiments of the above methods, the method further comprises contacting the sample with another compound, such as a candidate drug compound or any compound useful for measuring the amount of nitric oxide produced when the compound is contacted with the sample. In such embodiments, the compound can be contacted with the sample simultaneously with the compound of formula (I) or can be added to the sample after the compound of formula (I) has been added.

[0069] In cell-based assay embodiments, cells can be lysed in an appropriate cell lysis buffer. For animal cells, a buffer containing 0.1-1.0% of a non-ionic detergent such as Triton X 100 or Tergitol is typically sufficient. Bacterial, plant, fungal, or yeast cells are usually more difficult to lyse. Detergents, freeze / thaw cycles, hypotonic buffers, sonication, cavitation, or combinations of these methods can be used. The lysis method that produces the lysate is compatible with the detection of luciferase or other enzyme activity, or other molecules or conditions.

[0070] In any of the above embodiments, the sample can be contained in any suitable container, for example, the sample can be in a vial or in a well of a plate (e.g., a 96-well plate).

[0071] In some embodiments, rather than detecting luminescence directly in the wells of a plate (e.g., a 96-well plate) using a plate reader, luciferin released into the medium can be monitored by removing a small amount of medium from the sample and detecting luminescence in the removed medium, providing kinetic information on nitric oxide production.

[0072] The present disclosure further provides a system or kit comprising a compound described herein (i.e., a compound of formula (I), or a salt thereof). The system or kit comprises the compound alone or in a solvent, such as water, DMSO, or a buffer. If the compound is provided alone, the system or kit can further comprise a solvent in which the compound can be dissolved. The system or kit can further comprise one or more reagents, such as those described above, used to perform the assay and detect nitric oxide in a sample. The system or kit can further comprise instructions, such as instructions for performing the assay and detecting nitric oxide in a sample.

[0073] The following examples further illustrate aspects of the present disclosure but, of course, should not be construed as in any way limiting its scope. EXAMPLES

[0074] The following abbreviations are used in the examples: AcOH is acetic acid, DCE is dichloroethane, DIPEA is N,N-diisopropylethylamine, DMF is N,N-dimethylformamide, DMSO is dimethylsulfoxide, ES is electrospray, EtOAc is ethyl acetate, h is hour, HPLC is high performance liquid chromatography, LCMS is liquid chromatography mass spectrometry, MeCN is acetonitrile, TFA is trifluoroacetic acid, and THF is tetrahydrofuran.

[0075] Example 1: Synthesis of Compounds Intermediate 1: 6-((3-((tert-butyldimethylsilyl)oxy)propyl)amino)benzo[d]thiazole-2-carbonitrile [ka]

[0076] To a 20 mL vial was added 6-aminobenzo[d]thiazole-2-carbonitrile (100 mg, 0.571 mmol), 3-((tert-butyldimethylsilyl)oxy)propanal (118 mg, 0.628 mmol), DCE (1.5 mL), and AcOH (0.034 mL, 0.57 mmol). The mixture was stirred at 60° C. for 15 min. The mixture was cooled to room temperature. To the mixture was added sodium triacetoxyborohydride (181 mg, 0.856 mmol). After 1 h, the mixture was purified by silica gel chromatography eluting with 0→50% EtOAc in heptane as eluent to give intermediate 1, 6-((3-((tert-butyldimethylsilyl)oxy)propyl)amino)benzo[d]thiazole-2-carbonitrile. LCMS (C 17 H 25 N3OSSi)(ES,m / z)348 [M+H] + .

[0077] Compound 1: N-(2-cyanobenzo[d]thiazol-6-yl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide [ka]

[0078] To a 20 mL vial was added triphosgene (84.7 mg, 0.285 mmol) and THF (3 mL). The mixture was stirred. To the mixture was added a solution of 6-aminobenzo[d]thiazole-2-carbonitrile (100 mg, 0.571 mmol) and DIPEA (0.399 mL, 2.28 mmol) in THF (3 mL) dropwise. After 5 min, to the mixture was added N-(4-nitrophenyl)hydrazinecarbothioamide (242 mg, 1.14 mmol). After 30 min, the mixture was concentrated and purified by reverse phase HPLC (MeCN / water w / 0.1% TFA) to give compound 1, N-(2-cyanobenzo[d]thiazol-6-yl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide. LCMS (C 16 H 11 N7O3S2)(ES,m / z)414[M+H] + . 1H NMR(400MHz,DMSO-d6)δ 10.27 (s, 1H), 9.99 (s, 1H), 9.55 (s, 1H), 8.59 (d, J = 13.8 Hz, 2H), 8.20 (dd, J = 19.2, 8.5 Hz, 3H), 7.98 (d, J = 8.7 Hz, 2H), 7.77 (d, J = 9.1 Hz, 1H).

[0079] The compounds in Table 1 below were prepared in a manner similar to that for Compound 1. [Table 1]

[0080] Compound 5: N-(2-cyanobenzo[d]thiazol-6-yl)-N-(3-hydroxypropyl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide Step 1: N-(3-((tert-butyldimethylsilyl)oxy)propyl)-N-(2-cyanobenzo[d]thiazol-6-yl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide [ka]

[0081] N-(3-((tert-butyldimethylsilyl)oxy)propyl)-N-(2-cyanobenzo[d]thiazol-6-yl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide was prepared from intermediate 1 in a similar manner to that for compound 1. LCMS (C 25 H 31 N7O4S2Si)(ES,m / z)586[M+H] + .

[0082] Step 2: N-(2-cyanobenzo[d]thiazol-6-yl)-N-(3-hydroxypropyl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide [ka]

[0083] To a 20 mL vial was added N-(3-((tert-butyldimethylsilyl)oxy)propyl)-N-(2-cyanobenzo[d]thiazol-6-yl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide (22.7 mg, 0.0388 mmol), THF (1 mL), AcOH (1 mL), and water (0.5 mL). The mixture was stirred at room temperature. After 5 h, the solvent was evaporated. The residue was purified by reverse phase HPLC (MeCN / water w / 0.1% TFA) to give compound 5, N-(2-cyanobenzo[d]thiazol-6-yl)-N-(3-hydroxypropyl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide. LCMS (C 19 H 17N7O4S2)(ES, m / z)472[M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 10.13 (d, J = 245.7 Hz, 1H), 8.58 (d, J = 25.8 Hz, 1H), 8.45 - 8.27 (m, 2H), 8.22 (d, J = 8.7 Hz, 2H), 7.95 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 9.3 Hz, 1H), 4.44 (s, 1H), 3.83 (d, J = 8.3 Hz, 3H), 3.11 (s, 1H), 1.67 (s, 2H). The NMR spectrum indicates the presence of rotamers.

[0084] Compound 6: (S)-2-(6-(2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamido)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid [ka]

[0085] To a 20 mL vial containing compound 1, N-(2-cyanobenzo[d]thiazol-6-yl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide (20.0 mg, 0.0484 mmol), was added DMF (5 mL). The mixture was stirred. To the mixture was added a solution of D-cysteine ​​(7.0 mg, 0.058 mmol) in pH 8 phosphate buffer (1.5 mL). The mixture was purified by reverse phase HPLC (MeCN / water w / 0.1% TFA) to give compound 6, (S)-2-(6-(2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid. LCMS (C 19 H 15 N7O5S3) (ES, m / z) 518 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 10.26 (s, 1H), 9.98 (s, 1H), 9.41 (s, 1H), 8.56 (s, 1H), 8.45 (s, 1H), 8.22 (d, J = 8.7 Hz, 2H), 8.07 (d, J = 8.9 Hz, 1H), 7.99 (d, J = 8.7 Hz, 2H), 7.64 (d, J = 9.0 Hz, 1H), 5.43 (t, J = 9.1 Hz, 1H), 3.79 (t, J = 10.6 Hz, 1H), 3.69 (dd, J = 11.2, 8.4Hz, 1H).

[0086] The compounds in Table 2 below were prepared in a manner similar to that of compound 6. [Table 2]

[0087] Compound 11: Methyl (S)-2-(6-(2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamido)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylate [ka]

[0088] To a 20 mL vial containing compound 1, N-(2-cyanobenzo[d]thiazol-6-yl)-2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide (7.7 mg, 0.0186 mmol), was added DMF (2 mL). The mixture was stirred. To the mixture was added a solution of D-cysteine ​​methyl ester (3.0 mg, 0.022 mmol) in pH 8 phosphate buffer (1 mL). The mixture was purified by reverse phase HPLC (MeCN / water w / 0.1% TFA) to give compound 11 (methyl (S)-2-(6-(2-((4-nitrophenyl)carbamothioyl)hydrazine-1-carboxamide)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylate). LCMS (C 20 H 17 N7O5S3)(ES,m / z)532[M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 10.26 (s, 1H), 10.11 - 9.86 (m, 1H), 9.42 (s, 1H), 8.56 (s, 1H), 8.45 (s, 1H), 8.22 (dd, J = 9.1, 2.6 Hz, 2H), 8.12 - 8.04 (m, 1H), 7.99 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 9.1 Hz, 1H), 6.51 (d, J = 16.7 Hz, 1H), 5.54 (t, J = 9.2 Hz, 1H), 3.82 (t, J = 10.7 Hz, 1H), 3.77 (s, 3H), 3.71 (t, J = 9.6 Hz, 1H).

[0089] Example 2: Cell-free nitric oxide detection The cell-free detection and specificity of nitric oxide (NO) was compared with that of the known NO donor NONOate (100 μM) using reactive oxygen species (hypoxanthine (HX); 25 μM), xanthine oxidase (XO; 0.2 unit / mL), superoxide dismutase (SOD 1 unit / mL), hydrogen peroxide (HO20.03%), singlet oxygen (Rose Bengal; 25 μM), and reactive nitrogen species (sodium nitrite; 100 μM and peroxynitrite: 50 μM). The NO probe (compound 6, 25 μM) was combined with the analyte in a well of a 96-well assay plate containing PBS. Each well of the 96-well assay plate contained 50 μL of nitric oxide probe and 50 μL of analyte. After 30 min incubation at room temperature, 100 μL of luciferin detection reagent (Promega) was added and luminescence was measured using a GloMax (Promega) luminometer. Data are shown in Figure 3 (RLU = relative light units).

[0090] Example 3: Detection of intracellular nitric oxide following synergistic NO stimulation by lipopolysaccharide (LPS) and interferon gamma (INFγ) TIB71 macrophage cells (30,000 cells per well) were seeded into wells of a 96-well assay plate containing 100 μL of DMEM medium containing 10% FBS. The next day, the medium was removed and replaced with fresh DMEM medium containing 10% FBS and nitric oxide probe (compound 6, 25 μM) binding medium (control), LPS (1 ug / mL), and / or INFγ (1 ng / mL). After 24 hours of incubation at 37°C in a tissue culture incubator, 1 volume of luciferin detection reagent (Promega) was added and luminescence was measured using a GloMax (Promega) luminometer. Data are shown in Figure 4 (RLU = relative light units).

[0091] Example 4: Detection of nitric oxide in SIN-1 treated cells Under physiological conditions, SIN-1 generates superoxide (SO) and nitric oxide (NO) (see FIG. 5A). NO reacts rapidly with SO to form peroxynitrite. MitoTEMPO is an SO scavenger that reduces SO levels and subsequently increases NO. Five cell lines (30,000 cells per well) were seeded into wells of a 96-well assay plate and incubated overnight at 37°C in a tissue culture incubator. The next day, the NO probe (compound 6, 25 μM) was combined with medium (control), SIN-1 (100 μM), or SIN-1 (100 μM) and MitoTEMPO (200 μM). After 2 h of incubation at 37°C, one volume of luciferin detection reagent (Promega) was added and luminescence was measured using a GloMax (Promega) luminometer. Data are shown in FIG. 5B (RLU = relative light units).

[0092] All references cited in this specification, including publications, patent applications, and patents, are herein incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and is hereby incorporated by reference in its entirety.

[0093] In the context of the description of the invention (particularly in the context of the claims which follow), the use of the terms "a," "an," and "the," as well as "at least one," and similar referents, should be construed to encompass both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term "at least one" followed by one or more items (e.g., "at least one of A and B") should be construed to mean one item (A or B) selected from the listed items, or any combination of two or more of the listed items, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" should be construed to be open-ended (i.e., meaning "including but not limited to"), unless otherwise stated. The recitation of ranges of values ​​herein is intended to serve merely as a shorthand method of individually referring to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated herein as if it were individually recited herein. All methods described herein may be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by context. Any and all examples provided herein, or the use of exemplary language (e.g., "etc.") are intended merely to better illuminate the invention, and do not pose limitations on the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0094] Preferred embodiments of the invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of these preferred embodiments may become apparent to those of skill in the art upon reading the foregoing description. The inventors anticipate that such variations will be employed by those of skill in the art as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is included in the invention unless otherwise indicated herein or clearly contradicted by context.

Claims

1. Compounds of formula (I): [Formula 1] Or its salt. [In the formula: R 1 is -CN and [chemical 2] Selected from: R 2 is selected from hydrogen and halo; R 3 is hydrogen, C 1 -C 6 Alkyl and hydroxy-C 1 -C 6 - alkyl; n is 0, 1, 2, or 3; Each R 4 is independent, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 1 -C 6 Heteroalkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkyl, C 1 -C 6 Haloalkoxy, halo, hydroxy, amino, cyano, nitro, -COOR a , and -CONR b R c Selected from: R 5 is hydrogen and C 1 -C 4 alkyl; and R a , R b , and R c are each independently hydrogen, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, and C 1 -C 6 Heteroalkyl is selected from the group consisting of

2. R 1 The compound according to claim 1, or a salt thereof, wherein

3. R 1 teeth [C3] 2. The compound of claim 1, wherein:

4. R 5 The compound according to claim 3, or a salt thereof, wherein is selected from hydrogen and methyl.

5. R 2 The compound according to any one of claims 1 to 4, or a salt thereof, wherein is hydrogen.

6. R 3 The compound according to any one of claims 1 to 5, or a salt thereof, wherein is hydrogen.

7. R 3 is hydroxy-C 2 -C 4 6. The compound according to claim 1, wherein -alkyl is aryl, or a salt thereof.

8. R 3 Ha-CH 2 CH 2 CH 2 8. The compound of claim 7, or a salt thereof, wherein:

9. The compound according to any one of claims 1 to 8, or a salt thereof, wherein n is 0.

10. The compound according to any one of claims 1 to 8, or a salt thereof, wherein n is 1.

11. R 4 is selected from methoxy and nitro, or a salt thereof.

12.

4. 2. The compound of claim 1, or a salt thereof, selected from:

13. 1. A method for detecting nitric oxide in a sample, comprising: Contacting the sample with a compound according to any one of claims 1 to 12, or a salt thereof; contacting the sample with a luciferin-utilizing luciferase if the luciferin-utilizing luciferase is not already present in the sample; detecting luminescence in the sample; and The detection method comprising the steps of:

14. The method of claim 13 , wherein the sample comprises a living cell.

15. The method of claim 14 , wherein the cell expresses the luciferin-utilizing luciferase.

16. 14. The method of claim 13, comprising adding the luciferin-utilizing luciferase to the sample.

17. The method of any one of claims 13 to 16, wherein the luciferin-utilizing luciferase is firefly luciferase or click beetle luciferase.

18. A kit comprising the compound according to any one of claims 1 to 12, or a salt thereof.

19. 20. The kit of claim 18, further comprising a luciferin-utilizing luciferase enzyme or a nucleotide sequence encoding a luciferin-utilizing luciferase enzyme.

20. 20. The kit of claim 18 or 19, further comprising a buffer reagent.